Previous Close | 1.9800 |
Open | 2.0000 |
Bid | 2.2100 x 0 |
Ask | 2.2300 x 0 |
Day's Range | 2.0000 - 2.2400 |
52 Week Range | 1.2200 - 5.8400 |
Volume | |
Avg. Volume | 43,772 |
Market Cap | 102.535M |
Beta (5Y Monthly) | 1.73 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2400 |
Earnings Date | Apr 10, 2024 - Apr 15, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.46 |
Subscribe to Yahoo Finance Plus to view Fair Value for TH.TO
Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers Separate data to highlight activity of sudocetaxel zendusortide (TH1902) to trigger the cGAS/STING pathway potentiate and anti-PD-L1 immunotherapy tumor cell killing MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative
Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical oncology research activities. The Company will continue to prioritize its ongoing Phase 1 clinical trial of sudocetaxel zendus
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company’s Audit Committee. “We welcome Jordan Zwick to the Board as an important addition to our esteemed group of